The Pharma Data

JANUARY 5, 2021

So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins. They indicate that the potential benefits over current protein and RNA-based approaches are “potency, selectivity, oral bioavailability, tissue distribution and central nervous system penetration.”.

RNA 52

RNA Protein Bioavailability DNA 52

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. In August 2014, Roche acquired InterMune for USD 8.3

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

Roots Analysis

JANUARY 28, 2024

Some of the areas she has worked on include protein design and engineering, metabolomics services, bioavailability enhancement technologies and services, plasmid DNA manufacturing, NAMPT inhibitors, and big data analytics in healthcare domain.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

The Pharma Data

DECEMBER 3, 2020

SOL-578 is a best-in-class checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity and oral bioavailability which targets the DNA Damage Response (DDR) network. Checkpoint kinases play a crucial role in the cellular response to DNA damage.

Licensing 52

Licensing Licensing Bioavailability DNA 52

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40